- Home
- SAGE vs KMDA Comparison
SAGE vs KMDA Comparison
Compare SAGE & KMDA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SAGE
- KMDA
- Stock Information
- Founded
- SAGE 2010
- KMDA 1990
- Country
- SAGE United States
- KMDA Israel
- Employees
- SAGE N/A
- KMDA N/A
- Industry
- SAGE Biotechnology: Pharmaceutical Preparations
- KMDA Biotechnology: Pharmaceutical Preparations
- Sector
- SAGE Health Care
- KMDA Health Care
- Exchange
- SAGE Nasdaq
- KMDA Nasdaq
- Market Cap
- SAGE 474.6M
- KMDA 426.0M
- IPO Year
- SAGE 2014
- KMDA N/A
- Fundamental
- Price
- SAGE $7.77
- KMDA $6.71
- Analyst Decision
- SAGE Hold
- KMDA Strong Buy
- Analyst Count
- SAGE 19
- KMDA 3
- Target Price
- SAGE $9.88
- KMDA $14.67
- AVG Volume (30 Days)
- SAGE 1.2M
- KMDA 141.9K
- Earning Date
- SAGE 04-24-2025
- KMDA 03-05-2025
- Dividend Yield
- SAGE N/A
- KMDA 2.98%
- EPS Growth
- SAGE N/A
- KMDA 66.67
- EPS
- SAGE N/A
- KMDA 0.25
- Revenue
- SAGE $41,243,000.00
- KMDA $160,953,000.00
- Revenue This Year
- SAGE $100.39
- KMDA $11.45
- Revenue Next Year
- SAGE $70.86
- KMDA $9.94
- P/E Ratio
- SAGE N/A
- KMDA $26.72
- Revenue Growth
- SAGE N/A
- KMDA 12.93
- 52 Week Low
- SAGE $4.62
- KMDA $4.74
- 52 Week High
- SAGE $17.51
- KMDA $9.15
- Technical
- Relative Strength Index (RSI)
- SAGE 48.49
- KMDA 43.61
- Support Level
- SAGE $7.99
- KMDA $6.44
- Resistance Level
- SAGE $8.81
- KMDA $6.81
- Average True Range (ATR)
- SAGE 0.31
- KMDA 0.22
- MACD
- SAGE -0.06
- KMDA -0.02
- Stochastic Oscillator
- SAGE 9.57
- KMDA 34.88
About SAGE Sage Therapeutics Inc.
Sage Therapeutics Inc is a clinical-stage biopharmaceutical company focused on brain health medicines. The company is targeting diseases and disorders of the brain with three key focus areas: depression, neurology and neuropsychiatry; also targeting two critical central nervous system, or CNS, receptor systems, GABA and NMDA. Its products ZURZUVAE is a medicine for the treatment of postpartum depression, or PPD, in adults, and ZULRESSO is a CIV injection for the treatment of postpartum depression in individuals 15 years old and older. It also has other drugs in its pipeline such as SAGE-324, Dalzanemdor (SAGE-718) among others.
About KMDA Kamada Ltd.
Kamada Ltd is a drug-focused, plasma-derived protein therapeutics company. It is involved in the business of developing, producing, and marketing specialty therapeutics using protein purification proprietary technology. Its product portfolio consists of Glassia, Bramitob, Foster, Ixiaro, Factor-IX, and others. The company has two segments namely, Proprietary Products segment and Distribution segment. It derives the majority of its revenue from the Proprietary products segment. The firm categorizes its products in Lung Disease, Vaccines, Haemophilia, Immunoglobulins, Critical care, and Diagnostics.